5-day nonobserved artesunate monotherapy for treating uncomplicated Falciparum malaria in young Gabonese children.
Despite different recommendations from WHO and national authorities, artesunate monotherapy is increasingly used for treating African children with malaria. A 5-day course of oral artesunate (first day: 4 mg/kg body weight, observed intake; and 2 mg/kg body weight on the following days with nonobserved drug intake) yielded a PCR-corrected Day 28 cure rate of 90% (45 of 50 patients; CI 78-97%) in Gabonese children aged between 2 and 18 months. Artesunate was well tolerated, and no severe adverse events were reported.
Schwarz
Norbert G
NG
Medical Research Unit, Albert Schweitzer Hospital Lambaréné, Gabon.
Oyakhirome
Sunny
S
Pötschke
Marc
M
Gläser
Benjamin
B
Klein Klouwenberg
Peter
P
Altun
Handan
H
Adegnika
Ayola A
AA
Issifou
Saadou
S
Kun
Jürgen F J
JF
Kremsner
Peter G
PG
Grobusch
Martin P
MP
D000818:Animals; D000962:Antimalarials / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D037621:Artemisinins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000077332:Artesunate; D005260:Female; D005681:Gabon; D006801:Humans; D007223:Infant; D016778:Malaria, Falciparum / Q000188:drug therapy* / Q000469:parasitology; D008297:Male; D018512:Parasitemia / Q000188:drug therapy / Q000469:parasitology; D010963:Plasmodium falciparum / Q000145:classification / Q000187:drug effects* / Q000235:genetics; D012717:Sesquiterpenes / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
D000962:Antimalarials; D037621:Artemisinins; D012717:Sesquiterpenes; D000077332:Artesunate